Published in PLoS One on September 14, 2015
Posttranslational Modifications and the Immunogenicity of Biotherapeutics. J Immunol Res (2016) 0.76
How to measure and predict the molar absorption coefficient of a protein. Protein Sci (1995) 18.71
A beta oligomers - a decade of discovery. J Neurochem (2007) 8.88
RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature (1996) 7.04
Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem (1992) 5.60
Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A (2001) 5.60
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci (2012) 4.92
Effects of protein aggregates: an immunologic perspective. AAPS J (2006) 4.74
Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol (2013) 4.33
Human LilrB2 is a β-amyloid receptor and its murine homolog PirB regulates synaptic plasticity in an Alzheimer's model. Science (2013) 3.59
Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today (1991) 3.35
Immunoglobulin G: functional sites. Mol Immunol (1985) 3.12
Conformational Abs recognizing a generic amyloid fibril epitope. Proc Natl Acad Sci U S A (2002) 2.62
Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med (2000) 2.44
The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. Biophys J (2000) 2.37
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. Brain (2010) 2.29
Protein aggregation and its inhibition in biopharmaceutics. Int J Pharm (2005) 2.26
18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging (2008) 2.24
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Familial amyloid polyneuropathy. Lancet Neurol (2011) 2.15
Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med (2012) 2.01
Conformational isomerism and the diversity of antibodies. Proc Natl Acad Sci U S A (1994) 1.99
Transthyretin sequesters amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci U S A (1994) 1.94
Amyloid beta-protein dimers rapidly form stable synaptotoxic protofibrils. J Neurosci (2010) 1.92
Heterogeneity of monoclonal antibodies. J Pharm Sci (2008) 1.87
Untangling amyloid-β, tau, and metals in Alzheimer's disease. ACS Chem Biol (2013) 1.82
Transthyretin-related amyloidoses and the heart: a clinical overview. Nat Rev Cardiol (2010) 1.81
RAGE-mediated signaling contributes to intraneuronal transport of amyloid-beta and neuronal dysfunction. Proc Natl Acad Sci U S A (2009) 1.74
Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science (1989) 1.71
Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. Biochim Biophys Acta (2004) 1.60
Intravenous immunoglobulin expands regulatory T cells via induction of cyclooxygenase-2-dependent prostaglandin E2 in human dendritic cells. Blood (2013) 1.48
Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety. Biotechnol J (2006) 1.42
Intrinsically stable IgG aggregates. J Immunol Methods (1981) 1.41
Transthyretin (TTR) cardiac amyloidosis. Circulation (2012) 1.40
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
Intravenous immunoglobulins--understanding properties and mechanisms. Clin Exp Immunol (2009) 1.34
What is the contents of the magic draft IVIg? Autoimmun Rev (2008) 1.31
Naturally occurring auto-antibodies in homeostasis and disease. Trends Immunol (2008) 1.28
Naturally occurring autoantibodies against beta-amyloid: investigating their role in transgenic animal and in vitro models of Alzheimer's disease. J Neurosci (2011) 1.26
Human anti-beta-amyloid antibodies block beta-amyloid fibril formation and prevent beta-amyloid-induced neurotoxicity. Brain (2003) 1.24
Medin: an integral fragment of aortic smooth muscle cell-produced lactadherin forms the most common human amyloid. Proc Natl Acad Sci U S A (1999) 1.24
Senile systemic amyloidosis: clinical features at presentation and outcome. J Am Heart Assoc (2013) 1.20
Natural human antibodies to amyloid beta peptide. Autoimmun Rev (2008) 1.20
Intravenous immunoglobulins as a treatment for Alzheimer's disease: rationale and current evidence. Drugs (2010) 1.20
Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease. J Neuroinflammation (2010) 1.18
Site-specific blockade of RAGE-Vd prevents amyloid-beta oligomer neurotoxicity. J Neurosci (2008) 1.15
Intravenous immunoglobulin: exploiting the potential of natural antibodies. Autoimmun Rev (2012) 1.15
The structural basis of antibody-antigen recognition. Front Immunol (2013) 1.14
A molecular history of the amyloidoses. J Mol Biol (2012) 1.11
Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm (2003) 1.11
Amyloid-β oligomer specificity mediated by the IgM isotype--implications for a specific protective mechanism exerted by endogenous auto-antibodies. PLoS One (2010) 1.10
Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. J Infect Dis (2004) 1.10
FcγRIIb mediates amyloid-β neurotoxicity and memory impairment in Alzheimer's disease. J Clin Invest (2013) 1.08
Conformational changes of the amyloid beta-peptide (1-40) adsorbed on solid surfaces. Macromol Biosci (2005) 1.06
Site-directed mutagenesis of proteolytic antibody light chain. J Mol Biol (1995) 1.03
Isolation of low-n amyloid β-protein oligomers from cultured cells, CSF, and brain. Methods Mol Biol (2011) 1.03
Antibody: the flexible adaptor molecule. Trends Biochem Sci (1990) 1.02
Improvement of a low pH antigen-antibody dissociation procedure for ELISA measurement of circulating anti-Abeta antibodies. BMC Neurosci (2007) 1.00
Diagnostic and therapeutic potential of amyloid-reactive IgG antibodies contained in human sera. J Immunol (2006) 0.98
Human plasma contains cross-reactive Abeta conformer-specific IgG antibodies. Biochemistry (2008) 0.96
AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PLoS One (2012) 0.96
Intravenous immunoglobulin and Alzheimer's disease immunotherapy. Curr Opin Mol Ther (2007) 0.95
Quantitative and mechanistic studies of Abeta immunotherapy. CNS Neurol Disord Drug Targets (2009) 0.94
Superantigen properties of a human sialoprotein involved in gut-associated immunity. J Clin Invest (1995) 0.93
Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics. Pharm Res (2015) 0.92
Novel unconventional binding site in the variable region of immunoglobulins. Proc Natl Acad Sci U S A (1996) 0.91
Bevacizumab. Anti-VEGF monoclonal antibody, avastin, rhumab-VEGF. Drugs R D (2002) 0.90
Anti-amyloidogenic activity of IgGs contained in normal plasma. J Clin Immunol (2010) 0.88
IVIg protects the 3xTg-AD mouse model of Alzheimer's disease from memory deficit and Aβ pathology. J Neuroinflammation (2014) 0.88
Pathological proteins in senile plaques. Tohoku J Exp Med (1994) 0.86
Theory of proteolytic antibody occurrence. Immunol Lett (2005) 0.86
Kinetic assay for high-throughput screening of in vitro transthyretin amyloid fibrillogenesis inhibitors. J Comb Chem (2005) 0.86
Studies of the IgM and IgA contamination obtained by eluting IgG from protein A-Sepharose column with pH steps. J Immunol Methods (1980) 0.85
Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide. J Clin Immunol (2010) 0.83
Human lysozyme inhibits the in vitro aggregation of Aβ peptides, which in vivo are associated with Alzheimer's disease. Chem Commun (Camb) (2013) 0.83
Intravenous immunoglobulin and Alzheimer's disease: what now? J Neuroinflammation (2013) 0.83
Mechanisms of immune regulation by IVIG. Curr Opin Allergy Clin Immunol (2014) 0.83
Increased levels of antigen-bound β-amyloid autoantibodies in serum and cerebrospinal fluid of Alzheimer's disease patients. PLoS One (2013) 0.82
Antibodies as specific chaperones. Biochemistry (Mosc) (2004) 0.82
Binding of human proteins to amyloid-β protofibrils. ACS Chem Biol (2014) 0.81
Physiological IgM class catalytic antibodies selective for transthyretin amyloid. J Biol Chem (2014) 0.81
Chaperone-like antibodies targeting misfolded tau protein: new vistas in the immunotherapy of neurodegenerative foldopathies. J Alzheimers Dis (2008) 0.80
A generic method for design of oligomer-specific antibodies. PLoS One (2014) 0.79
Transthyretin aggregate-specific antibodies recognize cryptic epitopes on patient-derived amyloid fibrils. Rejuvenation Res (2014) 0.79
Utilizing dynamic light scattering as a process analytical technology for protein folding and aggregation monitoring in vaccine manufacturing. J Pharm Sci (2013) 0.78
Antigen-bound and free β-amyloid autoantibodies in serum of healthy adults. PLoS One (2012) 0.78
Conformational heterogeneity in antibody-protein antigen recognition: implications for high affinity protein complex formation. J Biol Chem (2014) 0.77
Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide. PLoS One (2012) 0.77
Binding of IgG to amyloid beta A4 peptide via the heavy-chain hinge region with preservation of antigen binding. J Neuroimmunol (1993) 0.76